Preparation of aspirin sustained-release microsphere and its in vitro releasing

  • Ying CHEN ,
  • Zhong-ning LIU ,
  • Bo LI ,
  • Ting JIANG
Expand
  • 1. Department of Prosthodontics, Peking University School and Hospital of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Laboratory for Digital and Material Technology of Stomatology & Beijing Key Laboratory of Digital Stomatology, Beijing 100081, China
    2. Chongqing Key Laboratory of Nano/Micro Composite Materials and Devices, Chongqing University of Science and Technology, Chongqing 401331, China

Received date: 2017-09-28

  Online published: 2019-10-24

Supported by

Supported by the Youth Program of National Natural Science Foundation of China(81400498);the General Program of National Natural Science Foundation of China(81771045);the Natural Science Key Foundation Project of Chongqing(CSTC2016JCYJA0541);and the Scientific and Technological Research Program of Chongqing Municipal Education Commission(KJ1601301)

Abstract

Objective: It has been proven that acetylsalicylic acid (aspirin), as a kind of classical non-steroidal anti-inflammatory drug, not only has the effect of anti-inflammatory, but also has the function of immunity regulation and mineralization. However, it needs further investigation to study how to delay release of aspirin for a long time and enable to promote bone regeneration. Herein, we demonstrated that the long-term delayed release pattern of aspirin through the construction of microsphere scaffolds is promising to achieve the excellent bone regeneration. Methods: Here we synthesized three kinds of scaffolds as follows: (1) aspirin loaded calcium silicate (CaSiO3) microsphere (CaSiO3-aspirin) via simple immersion; (2) aspirin loaded polylactic-co-glycolic acid (PLGA) microsphere (PLGA-aspirin) via oil/water (O/W) emulsion; (3) aspirin loaded PLGA-CaSiO3 scaffold (PLGA-CaSiO3-aspirin) via O/W emulsion, optimal morphology and structure of PLGA-CaSiO3-aspirin scaffold was acquired through modulating the ratio between PLGA and CaSiO3. Furthermore, spectrophotometer was used to monitor the concentration of the extract of the three scaffolds for different releasing time, including 1, 2, 4, 6, 9, 13, 17, 21, 24, 30, 36, and 45 days, aspirin loading efficiency and its accumulation releasing curves were both achieved according to the concentration of aspirin. Their sustained release effects of aspirin were evaluated eventually. Results: Environmental scanning electron microscope (ESEM) results showed that the surface structure of the three kinds of scaffolds were smooth and had uniform size distribution. In addition, a small amount of PLGA-aspirin microspheres occurred to aggregation, while a small amount of CaSiO3-aspirin microspheres were broken. Moreover, the PLGA-aspirin microspheres in the PLGA-CaSiO3-aspirin scaffolds were uniformly adhered to the surface of CaSiO3 microspheres. The aspirin loadings of CaSiO3-aspirin, PLGA-aspirin, and PLGA-CaSiO3-aspirin were (1.06±0.04)%, (7.05±0.06)%, and (6.75±0.18)%, respectively. In addition, their corresponding time for releasing 95% of aspirin was 3, 24, and 36 days, respectively. The releasing time of PLGA-CaSiO3-aspirin was longer than that of the others and the releasing rate was more stable. Conclusion: The microsphere scaffold of PLGA-CaSiO3-aspirin composites has excellent delayed-release effect on aspirin, which is promising for using as osteogenic materials.

Cite this article

Ying CHEN , Zhong-ning LIU , Bo LI , Ting JIANG . Preparation of aspirin sustained-release microsphere and its in vitro releasing[J]. Journal of Peking University(Health Sciences), 2019 , 51(5) : 907 -912 . DOI: 10.19723/j.issn.1671-167X.2019.05.019

References

[1] Carbone LD, Tylavsky FA, Cauley JA , et al. Association between bone mineral density and the use of nonsteroidal anti-inflammatory drugs and aspirin: impact of cyclooxygenase selectivity[J]. J Bone Miner Res, 2003,18(10):1795-1802.
[2] Kwon MS, Shim EJ, Seo YJ , et al. Effect of aspirin and aceta-minophen on proinflammatory cytokine-induced pain behavior in mice[J]. Pharmacology, 2005,74(3):152-156.
[3] Li YF, Fang XQ, Jiang T . Minimally traumatic alveolar ridge augmentation with a tunnel injectable thermo-sensitive alginate scaffold[J]. J Appl Oral Sci, 2015,23(2):215-223.
[4] Fang XQ, Lei L, Jiang T , et al. Injectable thermosensitive alginate/β-tricalcium phosphate/aspirin hydrogels for bone augmentation[J]. J Biomed Mater Res Part B, 2018,106(5):1739-1751.
[5] Kim YH, Tabata Y . Dual-controlled release system of drugs for bone regeneration[J]. Adv Drug Deliver Rev, 2015,94(1):28-40.
[6] Pakulska MM, Miersch S, Shoichet MS , et al. Designer protein delivery: From natural to engineered affinity-controlled release systems[J]. Science, 2016, 351(6279): aac4750.
[7] Tang Y, Singh J . Controlled delivery of aspirin: Effect of aspirin on polymer degradation and in vitro release from PLGA based phase sensitive systems[J]. Int J Pharm, 2008,357(1-2):119-125.
[8] 张安阳, 范田园 . 运用人工神经网络和响应曲面法体外优化阿司匹林海藻酸钙胃漂浮微球[J]. 北京大学学报(医学版), 2010,42(2):197-201.
[9] Vasudev SC, Chandy T, Sharma CP . Development of chitosan/polyethylene vinyl acetate co-matrix: controlled release of aspirin- heparin for preventing cardiovascular thrombosis[J]. Biomaterials, 1997,18(5):375-381.
[10] Xu SF, Lin KL, Wang Z , et al. Reconstruction of calvarial defect of rabbits using porous calcium silicate bioactive ceramics[J]. Biomaterials, 2008,29(17):2588-2596.
[11] Wang C, Lin KL, Chang J , et al. Osteogenesis and angiogenesis induced by porous b-CaSiO3/PDLGA composite scaffold via activation of AMPK/ERK1/2 and PI3K/Akt pathways[J]. Biomaterials, 2013,34(1):64-77.
[12] Lin TH, Pajarinen J, Lu L , et al. NF-κB as a therapeutic target in inflammatory-associated bone diseases[J]. Adv Protein Chem Struct Biol, 2017,107:117-154.
[13] Yamaza T, Miura Y, Bi Y , et al. Pharmacologic stem cell based intervention as a new approach to osteoporosis treatment in rodents[J]. PLoS One, 2008,3(7):e2615.
[14] Yun YR, Jang JH, Jeon E , et al. Administration of growth factors for bone regeneration[J]. Regen Med, 2012,7(3):369-385.
[15] White AP, Vaccaro AR, Hall JA , et al. Clinical applications of BMP-7/OP-1 in fractures, nonunions and spinal fusion[J]. Int Orthop, 2007,31(6):735-741.
[16] Street J, Bao M, deGuzman L, et al. Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover[J]. Proc Natl Acad Sci USA, 2002,99(15):9656-9661.
[17] Almubarak S, Nethercott H, Freeberg M , et al. Tissue engineering strategies for promoting vascularized bone regeneration[J]. Bone, 2016,83:197-209.
[18] Zeng YP, Yang C, Li Y , et al. Aspirin inhibits osteoclastogenesis by suppressing the activation of NF-кB andMAPKs in RANKL-induced RAW264.7 cells[J]. Mol Med Rep, 2016,14(3):1957-1962.
[19] Liu Y, Wang L, Kikuiri T , et al. Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-γ and TNF-α[J]. Nat Med, 2011,17(12):1594-1601.
[20] Park JI, Venteicher AS, Hong JY , et al. Telomerase modulates Wnt signalling by association with target gene chromatin[J]. Nature, 2009,460(7251):66-72.
[21] Chin KY . A Review on the relationship between aspirin and bone health[J]. J Osteoporos, 2017,2017:3710959.
[22] Marco B, Francesca U, Fabiana Q , et al. Controlled drug delivery in tissue engineering[J]. Adv Drug Deliver Rev, 2008,60(2):229-242.
[23] Lin KL, Xia LG, Li HY . Enhanced osteoporotic bone regeneration by strontium-substituted calcium silicate bioactive ceramics[J]. Biomaterials, 2013,34(38):10028-10042.
[24] Hong MH, Choi HJ, Ko YM , et al. Engineered microstructure granules for tailored drug release rate[J]. Biotechnol Bioeng, 2015,112(9):1936-1947.
Outlines

/